MILAN, Italy, 1st October 2025 – Neopharmed Gentili S.p.A. (“Neopharmed”), a fast-growing Italian pharmaceutical company focused on high-value therapeutic solutions, today announced the successful closing of its acquisition of the European commercial operations for ORLADEYO® (berotralstat), a first-in-class oral treatment for hereditary angioedema (HAE), from BioCryst Pharmaceuticals, Inc.
Read moreA responsible and solid commitment to our people, the environment and the community
In 2025, Neopharmed Gentili renews and expands its ESG (Environmental, Social, and Governance) commitment through concrete initiatives that reflect a corporate culture guided by the centrality of health, both human and animal, by the values of solidarity and inclusion, and by responsibility toward the community in which it operates.
Read moreNeopharmed Gentili acquires the European ORLADEYO® Business from BioCryst Pharmaceuticals
Neopharmed Gentili (“Neopharmed”), an Italian pharmaceutical company active in the marketing of high-value therapeutic solutions, controlled by the Del Bono Family and two leading international private equity firms, Ardian and Renaissance Partners, announces the acquisition of the European ORLADEYO® (berotralstat) business from BioCryst Pharmaceuticals. ORLADEYO is the first oral, once-daily plasma kallikrein inhibitor indicated for the treatment of Hereditary Angioedema (HAE).
Read moreNeopharmed Gentili and Michael Page, as partners of the employment inclusion platform Super Job, promoted the “Concerts of Hope” initiative. The format, created by Musica su Roma, brought ten children with disabilities to the stage of Teatro dei Ginnasi in Rome to experience an afternoon of growth, sharing and creativity.
Read moreThe latest Edison Foundation Report dedicated to the FAB13, the historic multinationals, with Italian capital, of Made in Italy pharmaceuticals, part of Farmindustria, was presented Monday 17th at the Edison Foundation. In a dialogue between Professor Marco Fortis, Vice President of the Edison Foundation, and Doctor Sebastiano Barisoni, Executive Deputy Director of Radio24, the results obtained by the Italian pharmaceutical industry in the last 20 years were analyzed in terms of growth in production, employment, research and development, innovation and exports.
Read moreNeopharmed Gentili announces the private placement of €100.0 million Senior Secured Notes due 2030
Milan, February 14, 2025 – Neopharmed Gentili S.p.A., a joint stock company (società per azioni) incorporated under the laws of Italy (the “Issuer” or “Neopharmed”), has successfully priced €100.0 million of Senior Secured Notes due 2030 (the “New Notes”), in a tap issuance of the high-yield bond issued on April 8, 2024 (the “Tap Issuance”). The issuance and settlement of the New Notes is expected to occur on February 27, 2025, subject to customary closing conditions.
Read moreMilan, February 04, 2025 – Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian and NB Renaissance in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Sanofi for the acquisition of the rights in Italy and 14 other countries internationally to the Plasil® and Primperan® brands.
Read moreInclusion through sport: young athletes take center stage at Palaluiss sports afternoon
(Rome, September 16, 2024) – The annual InSport event took place today at the PalaLuiss in Rome, organized by SuperJob in collaboration with CORE, Michael Page, and Luiss University, with support of the main partner Neopharmed Gentili.
Read moreNeopharmed Gentili announces CEO transition
Milan, July 18, 2024 – Neopharmed Gentili S.p.A., a leading Italian primary care branded
pharmaceutical company, backed by Ardian and NB Renaissance together with the Del Bono family,
announces that CEO Eric Falcand has decided to step down from his position for personal reasons.
Alessandro Del Bono, who led the company prior to Eric’s appointment and is the current Chairman
of the Board, will continue leading the company until a new CEO is appointed by the Board of
Directors.
Milan, March 29, 2024 – Neopharmed Gentili S.p.A., a joint stock company (società per azioni) incorporated under the laws of Italy (the “Issuer” or “Neopharmed”), has successfully completed today the placement on the high-yield bond market (the “Offering”) of €750.0 million of Senior Secured Notes, consisting of €350.0 million in aggregate principal amount of Senior Secured Fixed Rate Notes due 2030 and €400.0 million in aggregate principal amount of Senior Secured Floating Rate Notes due 2030 (collectively, the “Notes”).
Read moreEric Falcand is the new CEO of Neopharmed Gentili
Milan, October, 31st 2023 – Eric Falcand is the new CEO of Neopharmed Gentili, a pharmaceutical company specialised in the commercialisation of high-value therapeutic solutions, historically rooted in Italy and rapidly expanding beyond national borders, controlled by private equity firms Ardian and NB Renaissance in partnership with the Del Bono family. Falcand succeeds Alessandro Del Bono, who will continue as Executive Chairman.
Read moreMilan, 9 March 2023– The pharmaceutical company Neopharmed Gentili participates with a donation of 50,000 euros in the fundraising launched by the Italian Red Cross (CRI) in favor of communities affected by the violent earthquake in Turkey and Syria. The funds will be used to support the activities of Volunteers and Red Cross operators engaged in the front line of operations to support populations who are experiencing a situation of serious difficulty.
Read moreMilan, 27 July 2022 – Neopharmed Gentili, an Italian pharmaceutical company specialized in the marketing of solutions with high therapeutic value, controlled by Ardian in partnership with the Del Bono family, has acquired 100% of Valeas, a historic Italian company with widely-recognized leadership in pediatric, broncho-pneumological, rhinological and neuropsychiatric (CNS) fields.
Read the press reviewNeopharmed Gentili acquires Lormetazepam product
Milan, 1st March, 2022- Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Bayer for the acquisition of the rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan). Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia.
Read moreNeopharmed Gentili acquires Lormetazepam product portfolio to strengthen its neurology division
Milan, 1st March, 2022 – Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Bayer for the acquisition of the rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan). Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia.
Read moreANNUAL REPORT SOCIAL 2020 NEOPHARMED GENTILI
SOCIAL MEDIA REPORT 2020 – TWITTER – INSTAGRAM – LINKEDIN
Press Release
PDF download
